RESUMEN
Thermal activation of CpW(NO)(CH(2)CMe(3))(2) (1) in neat hydrocarbon solutions transiently generates the neopentylidene complex, CpW(NO)(=CHCMe(3)) (A), which subsequently activates solvent C-H bonds. For example, the thermolysis of 1 in tetramethylsilane and perdeuteriotetramethylsilane results in the clean formation of CpW(NO)(CH(2)CMe(3))(CH(2)SiMe(3)) (2) and CpW(NO)(CHDCMe(3))[CD(2)Si(CD(3))(3)] (2-d(12)), respectively, in virtually quantitative yields. The neopentylidene intermediate A can be trapped by PMe(3) to obtain CpW(NO)(=CHCMe(3))(PMe(3)) in two isomeric forms (4a-b), and in benzene, 1 cleanly forms the phenyl complex CpW(NO)(CH(2)CMe(3))(C(6)H(5)) (5). Kinetic and mechanistic studies indicate that the C-H activation chemistry derived from 1 proceeds through two distinct steps, namely, (1) rate-determining intramolecular alpha-H elimination of neopentane from 1 to form A and (2) 1,2-cis addition of a substrate C-H bond across the W=C linkage in A. The thermolysis of 1 in cyclohexane in the presence of PMe(3) yields 4a-b as well as the olefin complex CpW(NO)(eta(2)-cyclohexene)(PMe(3)) (6). In contrast, methylcyclohexane and ethylcyclohexane afford principally the allyl hydride complexes CpW(NO)(eta(3)-C(7)H(11))(H) (7a-b) and CpW(NO)(eta(3)-C(8)H(13))(H) (8a-b), respectively, under identical experimental conditions. The thermolysis of 1 in toluene affords a surprisingly complex mixture of six products. The two major products are the neopentyl aryl complexes, CpW(NO)(CH(2)CMe(3))(C(6)H(4)-3-Me) (9a) and CpW(NO)(CH(2)CMe(3))(C(6)H(4)-4-Me) (9b), in approximately 47 and 33% yields. Of the other four products, one is the aryl isomer of 9a-b, namely, CpW(NO)(CH(2)CMe(3))(C(6)H(4)-2-Me) (9c) ( approximately 1%). The remaining three products all arise from the incorporation of two molecules of toluene; namely, CpW(NO)(CH(2)C(6)H(5))(C(6)H(4)-3-Me) (11a; approximately 12%), CpW(NO)(CH(2)C(6)H(5))(C(6)H(4)-4-Me) (11b; approximately 6%), and CpW(NO)(CH(2)C(6)H(5))(2) (10; approximately 1%). It has been demonstrated that the formation of complexes 10 and 11a-b involves the transient formation of CpW(NO)(CH(2)CMe(3))(CH(2)C(6)H(5)) (12), the product of toluene activation at the methyl position, which reductively eliminates neopentane to generate the C-H activating benzylidene complex CpW(NO)(=CHC(6)H(5)) (B). Consistently, the thermolysis of independently prepared 12 in benzene and benzene-d(6) affords CpW(NO)(CH(2)C(6)H(5))(C(6)H(5)) (13) and CpW(NO)(CHDC(6)H(5))(C(6)D(5)) (13-d(6)), respectively, in addition to free neopentane. Intermediate B can also be trapped by PMe(3) to obtain the adducts CpW(NO)(=CHC(6)H(5))(PMe(3)) (14a-b) in two rotameric forms. From their reactions with toluene, it can be deduced that both alkylidene intermediates A and B exhibit a preference for activating the stronger aryl sp(2) C-H bonds. The C-H activating ability of B also encompasses aliphatic substrates as well as it reacts with tetramethylsilane and cyclohexanes in a manner similar to that summarized above for A. All new complexes have been characterized by conventional spectroscopic methods, and the solid-state molecular structures of 4a, 6, 7a, 8a, and 14a have been established by X-ray diffraction methods.
RESUMEN
Treatment of [Cp*Mo(NO)Cl(mu-Cl)](2) with magnesium (Me(2)Mg.dioxane, MeMgCl) or aluminum (Me(3)Al) methylating reagents affords the known compound [Cp*Mo(NO)Me(mu-Cl)](2) (1). Similar treatment of the dichloro precursor with MeLi in ethereal solvents generates an equimolar mixture of 1 and the trimethyl "ate" complex, Cp*MoMe(3)(NO-Li(OEt(2)(n)), (2-Et(2)O). Reaction of 2-Et(2)O with a source of [Me](+) forms Cp*MoMe(3)(=N-OMe)(3), a rare terminal alkoxylimido complex. Metathesis of the chloro ligands of [Cp*Mo(NO)Cl(mu-Cl)](2) by MeLi in toluene at low temperatures produces the target dimethyl complex, Cp*Mo(NO)Me(2) (4), in 75% isolated yield. In solution, 4 is predominantly a monomeric species, whereas in the solid state it adopts a dimeric or oligomeric structure containing isonitrosyl bridges as indicated by IR and (15)N/(13)C NMR spectroscopies. Hydrolysis of 4 affords meso- and rac-[Cp*Mo(NO)Me](2)(mu-O) (5), and the reactions of 4 with a range of Lewis bases, L, to form the 18e adducts Cp*Mo(NO)(L)Me(2) (e.g., Cp*Mo(NO)(PMe(3))Me(2) (7)), have established it to be the most electrophilic complex of its family. Acidolysis of the methyl groups of 4 is also facile. Most notably, 4 is thermally unstable in solution and undergoes isomerization via nitrosyl N-O bond cleavage to its oxo(imido) form, Cp*Mo(NMe)(O)Me (11), which is isolable from the final reaction mixture as the mu-oxo-bridged adduct formed by 4 and 11, i.e., Cp*Mo(NO)Me(2)(mu-O)Cp*Mo(NMe)Me (4 <-- 11). The rate of this isomerization is significantly faster for the tungsten dimethyl complex; hence, Cp*W(NO)Me(2) (12) is not isolable free of a supporting donor interaction and can only be isolated as Cp*W(NO)Me(2)(mu-O)Cp*W(NMe)Me (12 <-- 13) or Cp*W(NO)Me(2)(PMe(3)) (14) adducts.
RESUMEN
Recent synthetic and theoretical investigations of organometallic compounds containing the CpCr(NO) fragment have shown an interdependence of the electronic nature of ancillary ligands and the stability of a given Cr oxidation state. Understanding the correlation between ligand pi-bonding properties and the nature of the metal-based frontier orbitals permits the rationalization of observed reactivity patterns, and the identification and preparation of new classes of target molecules.
RESUMEN
Nitrovasodilators cause endothelium-independent relaxation of blood vessels by generating nitric oxide (NO). We examined the relaxation and depressor effects of two organotransition-metal nitrosyl complexes, CpCr(NO)2Cl and CpMo(NO)2Cl, relative to those of the prototypal nitrovasodilators, nitroglycerin, and sodium nitroprusside (SNP), in phenylephrine-preconstricted aortic rings and conscious, unrestrained rats. CpCr(NO)2Cl, CpMo(NO)2Cl, nitroglycerin and SNP caused dose-dependent relaxation of aortic rings at maximal responses (Emax) of -118+/-4, -113+/-4, -104+/-1, and -128+/-5% and EC50 of 0.14+/-0.04, 22+/-4, 1.23+/-0.65, and 0.063+/-0.013 microM, respectively. The dose-response curve of CpCr(NO)2Cl was displaced to the right by hemoglobin, as well as methylene blue, showing involvement of the NO/cGMP pathway. Unlike nitroglycerin, preexposure for 1 h to CpCr(NO)2Cl did not alter subsequent relaxation response to the compound. Intravenous bolus injections of CpCr(NO)2Cl, CpMo(NO)2Cl, nitroglycerin, and SNP caused dose-dependent decreases in MAP with Emax of -42+/-2, -51+/-8, -56+/-6, and -58+/-2 mm Hg and EC50 of 0.041+/-0.010, 13+/-4, 1.6+/-0.4, and 0.037+/-0.004 micromol/kg, respectively. These results show that CpCr(NO)2Cl and CpMo(NO)2Cl are efficacious nitrovasodilators in vitro and in vivo.
